How did Invivyd's reported revenue and earnings per share compare to consensus analyst estimates for Q2 2025?

Bottom‑line vs. consensus

Invivyd posted $78.4 million in Q2‑2025 revenue, versus the $81.1 million consensus estimate from Street‑side analysts – a shortfall of roughly ‑3.5 %. On the earnings side, the company reported $0.12 EPS (diluted), which fell below the $0.15 consensus by about ‑20 %. Both top‑line and bottom‑line results missed the Street’s expectations, prompting a modest sell‑off in the post‑release session.

Trading implications

The revenue miss signals that the “rapid‑growth” pipeline of pre‑clinical services may still be lagging behind the aggressive guidance given in late‑2024, while the sub‑par EPS underscores higher‑than‑expected R&D spend and SG&A drag. In a relatively thin‑traded small‑cap biotech, the price reaction can be swift: IVVD opened near the prior close but slipped 3–4 % on the news, testing the $1.10–$1.15 support zone on the daily chart. If the stock holds above the 20‑day moving average (≈$1.12) and finds buying on the dip, it could stabilize; however, a breach below $1.10 may open the path to the next technical low around $0.95. Given the miss, a short‑position with a tight stop just above the recent high ($1.15) or a cautious “buy‑the‑dip” if the price rebounds to the 20‑day average would be the most disciplined approach.